Prevalence of aPL antibodies
| Autoantibody . | Clinical APS, n = 25 . | Nonclinical APS, n = 30 . | P . |
|---|---|---|---|
| aCL, IgG | 17 (56) | 20 (66) | NS |
| aCL, IgM | 21 (84) | 29 (96) | NS |
| aCL, any isotype | 25 (100) | 30 (100) | NS |
| Anti-β2GP-I IgG | 15 of 23 (65) | 15 of 29 (51) | NS |
| anti-β2GP-I IgM | 14 of 19 (73) | 23 of 28 (82) | NS |
| Anti-β2GP-I (any isoype) | 20 of 22 (90) | 25 of 28 (89) | NS |
| Lupus anticoagulant | 14 of 22 (63) | 9 of 27 (30) | .04* |
| Lupus anticoagulant + aCL (any isotype) | 14 of 22 (63) | 9 of 27 (30) | .04* |
| LAC + IgG aCL + IgG anti-β2GP-I | 8 of 21 (38) | 7 of 27 (26) | NS |
| Autoantibody . | Clinical APS, n = 25 . | Nonclinical APS, n = 30 . | P . |
|---|---|---|---|
| aCL, IgG | 17 (56) | 20 (66) | NS |
| aCL, IgM | 21 (84) | 29 (96) | NS |
| aCL, any isotype | 25 (100) | 30 (100) | NS |
| Anti-β2GP-I IgG | 15 of 23 (65) | 15 of 29 (51) | NS |
| anti-β2GP-I IgM | 14 of 19 (73) | 23 of 28 (82) | NS |
| Anti-β2GP-I (any isoype) | 20 of 22 (90) | 25 of 28 (89) | NS |
| Lupus anticoagulant | 14 of 22 (63) | 9 of 27 (30) | .04* |
| Lupus anticoagulant + aCL (any isotype) | 14 of 22 (63) | 9 of 27 (30) | .04* |
| LAC + IgG aCL + IgG anti-β2GP-I | 8 of 21 (38) | 7 of 27 (26) | NS |
Values are n (%).
aPL indicates anticardiolipin; β2GP-I, β2-glycoprotein-I ; CI, confidence interval; IgG, immunoglobulin G; IgA, immunoglobulin A; LAC, lupus anticoagulant test; NS, not significant; and OR, odds ratio.
OR, 3.5; 95% CI, 1.07-11.4), P < .02.